News

As per the terms of the agreement, Affectis Pharma will license exclusive rights to Merck for the development and commercialization of the proposed compounds. Affectis Pharma is entitled

Developed by GW Pharmaceuticals, Sativex (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) is in phase III clinical development for the treatment of cancer pain, as the next indication following MS

The virtual trial, being conducted under an investigational new drug (IND) application using electronic tools, allows patients to participate in the clinical trial regardless of their proximity to

EPI-743, an orally absorbed small molecule that readily crosses into the central nervous system, works by targeting an enzyme NADPH quinone oxidoreductase 1 (NQO1). EPI-743 is in phase

As per the agreement, Neuralstem will allow SPI to market the development and licensing rights to its neurogenic compound NSI-189. NSI-189, indicated as a treatment for major depression

The awarded money will be used by OPKO’s wholly-owned Mexican subsidiary Exakta-OPKO to enhance the development of research projects in ophthalmology, infectious disease and oncology. OPKO chairman and

Memary, an N-methyl-D-aspartate (NMDA) receptor antagonist, is the generic version of Memantine Hydrochloride, which was licensed from Merz Pharmaceuticals. Daiichi Sankyo has obtained the Japanese approval to manufacture

Watson‘s Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09mg/0.02mg are the generic version of Lybrel Tablets of Pfizer. Lybrel is indicated for the prevention of pregnancy in women who

The new solution extends the Monaco On Demand Reporting and Analytics platform with a visualization tool that provides real-time visibility into large sales and financial performance data sets.